Swedish Orphan Biovitrum hands back rights to Amgen's Mimpara
This article was originally published in Scrip
Executive Summary
Swedish Orphan Biovitrum is handing back the co-promotion rights to hyperparathyroid condition treatment Mimpara (cinacalcet) to Amgen as part of the company's refocused strategy.